EANS-News: Sangui Bio Tech International Inc. / SastoMed starts Granulox sales today

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Sales start

Subtitle: Ambitious sales targets, detailed marketing plan, focused
sales team

Witten, Germany, April 16, 2012 (euro adhoc) - Subsequent to the
granting of the CE mark authorizing production, distribution and
sales in the member countries of the European Union, and after
fifteen months of intensive strategic and operational preparation,
global licensee SastoMed GmbH has initiated sales of Granulox today
on the official approval of the first batch of products. Granulox, a
spray aiming at improved healing of chronic wounds, is based on a
patent by SanguiBioTech GmbH. It currently is the only therapeutic
which can help to soothe the problem of hypoxia i.e. the lack of
oxygen supply to chronic wounds. Indications as granted by the CE
mark include diabetic foot, leg ulcer and decubitus ulcer. "It is
worth noticing", SastoMed Managing Director Michael Sander
emphasized, "that thanks to our highly focused approach and diligent
professional work we managed to obtain the CE mark ahead of our 2010
schedule but are fully prepared now for a head start into actual
commercialization. This was our goal from the beginning and this
first part of the mission was fully accomplished." According to
information provided by the joint venture company, SastoMed GmbH over
the past months hired and trained a sales team of experienced wound
management experts who will now take care of the German market. They
will be supported by additional sales representatives. The sales team
is focused on Granulox exclusively. In the course of premarketing
activities multiple contacts among hospitals, wound ambulances and
wound care practitioners have already been made aware of the
advantages of Granulox. Based on the reaction by numerous experts,
SastoMed, therefore, is pursuing ambitious sales targets and expects
to having gained a 10% share of the market for modern wound treatment
by the end of 2013. The detailed marketing plan for the current year
includes advertisement campaigns in specialized trade media,
noticeable presence at key wound management conferences, congresses
and medical trade fairs including booths, hosting of workshops and
round table sessions as well as lectures and presentations, both in
Germany and on an international level. Negotiations are underway with
potential distributors in key European countries, SastoMed confirmed.
SastoMed also indicated that production capacity was contractually
secured to meet demand beyond the current ambitious sales targets.
Additional market assumptions and revenue expectations are to be
disclosed at some later point in time after the launch phase of the
sales initiatives. SanguiBioTech GmbH is a ninety percent subsidiary
of Sangui BioTech International, Inc. (www.otcmarkets.com: SGBI)

Further inquiry note:
Dr. Joachim Fleing
Fon: +49 (160) 741 27 17
Fax: +49 (2302) 915 191
e-mail: fleing@sangui.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Sangui Bio Tech International Inc.
Alfred-Herrhausen-Strasse 44
D-58455 Witten
phone: +49(0)2302 915-200
FAX: +49(0)2302 915-191
mail: info@sangui.de
WWW: http://www.sanguibiotech.com
sector: Biotechnology
ISIN: DE0000906757
indexes:
stockmarkets: free trade: Hamburg, New York
language: English